A Detailed Analysis of the Herpes Simplex Keratitis Treatment Market Based on Heightened Awareness, Improved Diagnostic Methods, and Ongoing Research for Enhancing Treatment Options
Report ID: PMRREP33990
Number of Pages: 219
Format: PPT*, PDF, EXCEL
Industry: Healthcare
Published Date: February-2024
1. Executive Summary
1.1. Global Herpes Simplex Keratitis Treatment Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Drug Lifecycle Analysis
2.4. Herpes Simplex Keratitis Treatment Market: Value Chain
2.4.1. List of Raw Material Supplier
2.4.2. List of Manufacturers
2.4.3. List of Distributors
2.4.4. List of Applications
2.4.5. Profitability Analysis
2.5. Porter Five Force’s Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
2.7.1. Global Sectorial Outlook
2.7.2. Global GDP Growth Outlook
2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Route of Administration Landscape
3. Global Herpes Simplex Keratitis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
3.1. Key Highlights
3.1.1. Market Volume (Units) Projections
3.1.2. Market Size and Y-o-Y Growth
3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
3.2.1. Historical Market Size Analysis, 2013-2016
3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global Herpes Simplex Keratitis Treatment Market Outlook: Drug
3.3.1. Introduction / Key Findings
3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Drug, 2018 - 2022
3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
3.3.3.1. Famciclovir
3.3.3.2. Valacyclovir
3.3.3.3. Acyclovir
3.3.3.4. Other Drugs
3.4. Market Attractiveness Analysis: Drug
3.5. Global Herpes Simplex Keratitis Treatment Market Outlook: Route of Administration
3.5.1. Introduction / Key Findings
3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Route of Administration, 2018 - 2022
3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
3.5.3.1. Topical
3.5.3.2. Injection
3.5.3.3. Oral
3.6. Market Attractiveness Analysis: Route of Administration
4. Global Herpes Simplex Keratitis Treatment Market Outlook: Region
4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
4.3.1. North America
4.3.2. Europe
4.3.3. East Asia
4.3.4. South Asia and Oceania
4.3.5. Latin America
4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region
5. North America Herpes Simplex Keratitis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
5.3.1. By Country
5.3.2. By Drug
5.3.3. By Route of Administration
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
5.4.1. U.S.
5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
5.5.1. Famciclovir
5.5.2. Valacyclovir
5.5.3. Acyclovir
5.5.4. Other Drugs
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
5.6.1. Topical
5.6.2. Injection
5.6.3. Oral
5.7. Market Attractiveness Analysis
6. Europe Herpes Simplex Keratitis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
6.3.1. By Country
6.3.2. By Drug
6.3.3. By Route of Administration
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
6.4.1. Germany
6.4.2. France
6.4.3. U.K.
6.4.4. Italy
6.4.5. Spain
6.4.6. Russia
6.4.7. Türkiye
6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
6.5.1. Famciclovir
6.5.2. Valacyclovir
6.5.3. Acyclovir
6.5.4. Other Drugs
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
6.6.1. Topical
6.6.2. Injection
6.6.3. Oral
6.7. Market Attractiveness Analysis
7. East Asia Herpes Simplex Keratitis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
7.3.1. By Country
7.3.2. By Drug
7.3.3. By Route of Administration
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
7.4.1. China
7.4.2. Japan
7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
7.5.1. Famciclovir
7.5.2. Valacyclovir
7.5.3. Acyclovir
7.5.4. Other Drugs
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
7.6.1. Topical
7.6.2. Injection
7.6.3. Oral
7.7. Market Attractiveness Analysis
8. South Asia & Oceania Herpes Simplex Keratitis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
8.3.1. By Country
8.3.2. By Drug
8.3.3. By Route of Administration
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
8.4.1. India
8.4.2. Southeast Asia
8.4.3. ANZ
8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
8.5.1. Famciclovir
8.5.2. Valacyclovir
8.5.3. Acyclovir
8.5.4. Other Drugs
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
8.6.1. Topical
8.6.2. Injection
8.6.3. Oral
8.7. Market Attractiveness Analysis
9. Latin America Herpes Simplex Keratitis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
9.3.1. By Country
9.3.2. By Drug
9.3.3. By Route of Administration
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
9.5.1. Famciclovir
9.5.2. Valacyclovir
9.5.3. Acyclovir
9.5.4. Other Drugs
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
9.6.1. Topical
9.6.2. Injection
9.6.3. Oral
9.7. Market Attractiveness Analysis
10. Middle East & Africa Herpes Simplex Keratitis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
10.3.1. By Country
10.3.2. By Drug
10.3.3. By Route of Administration
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
10.4.1. GCC
10.4.2. Egypt
10.4.3. South Africa
10.4.4. Northern Africa
10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
10.5.1. Famciclovir
10.5.2. Valacyclovir
10.5.3. Acyclovir
10.5.4. Other Drugs
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
10.6.1. Topical
10.6.2. Injection
10.6.3. Oral
10.7. Market Attractiveness Analysis
11. Competition Landscape
11.1. Market Share Analysis, 2022
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Injection
11.2.3. Apparent Product Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
11.3.1. GlaxoSmithKline
11.3.1.1. Overview
11.3.1.2. Segments and Product
11.3.1.3. Key Financials
11.3.1.4. Market Developments
11.3.1.5. Market Strategy
11.3.2. Vectans Pharma
11.3.2.1. Overview
11.3.2.2. Segments and Product
11.3.2.3. Key Financials
11.3.2.4. Market Developments
11.3.2.5. Market Strategy
11.3.3. Blistex
11.3.3.1. Overview
11.3.3.2. Segments and Product
11.3.3.3. Key Financials
11.3.3.4. Market Developments
11.3.3.5. Market Strategy
11.3.4. Bausch Health
11.3.4.1. Overview
11.3.4.2. Segments and Product
11.3.4.3. Key Financials
11.3.4.4. Market Developments
11.3.4.5. Market Strategy
11.3.5. Aurobindo Pharma
11.3.5.1. Overview
11.3.5.2. Segments and Product
11.3.5.3. Key Financials
11.3.5.4. Market Developments
11.3.5.5. Market Strategy
11.3.6. Dr. Reddy's Laboratories
11.3.6.1. Overview
11.3.6.2. Segments and Product
11.3.6.3. Key Financials
11.3.6.4. Market Developments
11.3.6.5. Market Strategy
11.3.7. Cipla
11.3.7.1. Overview
11.3.7.2. Segments and Product
11.3.7.3. Key Financials
11.3.7.4. Market Developments
11.3.7.5. Market Strategy
11.3.8. Jubilant Cadista
11.3.8.1. Overview
11.3.8.2. Segments and Product
11.3.8.3. Key Financials
11.3.8.4. Market Developments
11.3.8.5. Market Strategy
11.3.9. Mylan
11.3.9.1. Overview
11.3.9.2. Segments and Product
11.3.9.3. Key Financials
11.3.9.4. Market Developments
11.3.9.5. Market Strategy
11.3.10. Novartis International AG
11.3.10.1. Overview
11.3.10.2. Segments and Product
11.3.10.3. Key Financials
11.3.10.4. Market Developments
11.3.10.5. Market Strategy
12. Appendix
12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations